Hui Chuang, a Chinese medical device manufacturer received over CNY 100 million pre series B round funding, from Tao Capital and Founder security. The funds will be used to expand the company's sales channel as well as secure clinical trials.
DaFeng Zhang, Chairman of Tao Capital claimed, brain is the most difficult organ to diagnose, and that a thorough understanding of the structure and functions of the brain is the key to a successful diagnosis. Aside from that, China has a higher number of patients seeking treatment for brain diseases. Hui Chuang's Functional near-infrared spectroscopy (fNIRS) is a leading Near Infrared Spectroscopy brain image device that can provide a high-resolution image and is more stable and portable, as well as less expensive, bringing new diagnose and treatment methods for mental illnesses and recovery.
Hui Chuang's commitment to clinical trials has been praised by Keshu Wang, a partner at Changhai Capital, who believes Hui Chuang's innovation will greatly benefit patients.
In China, the demand for brain disease diagnosis and treatment is increasing, and the number of patients has surpassed 300 million, creating a market worth over $100 billion.
Huichuang made a breakthrough in the field of fNIRS. Their fNIRS products have disrupted the monopoly of foreign company in the fNIRS market. They'll also continue to look into new technology that combines electroencephalography, eye tracking, and transcranial magnetic stimulation, as well as the use of fRNS in brain-computer interfaces.